80
Participants
Start Date
March 22, 2023
Primary Completion Date
October 21, 2024
Study Completion Date
October 21, 2024
GDC-6599
GDC-6599 will be administered Days 1- 14 and on Days 29-42 as film-coated tablets
GDC-6599-matching placebo
GDC-6599-matching placebo will be administered Days 1- 14 and on Days 29- 42. as film-coated tablets
Mannitol
Mannitol challenge tests will be performed during screening and at least 2.5 hours following study drug administration at Study Visits 2, 4, 5 and 7
Box Hill Hospital; Eastern Clinical Research Unit, Box Hill
Mater Hospital Brisbane, South Brisbane
TrialsWest Pty Ltd, Spearwood
Clinical Research Associates Of Central Pa , Llc, DuBois
ADAC Research PA, Greenville
Pioneer Clinical Studies, Miami
Mayo Clinic, Rochester
Pharmaceutical Research & Consulting, Inc., Dallas
Southern California Institute For Respiratory, Los Angeles
California Medical Research Associates, Inc., Northridge
Bellingham Asthma, Allergy & Immunology, Bellingham
McMaster University Medical Centre, Hamilton
Diex Recherche - Québec - HyperCore - PPDS, Québec
Belfast City Hospital, Belfast
West Walk Surgery, Bristol
Royal Infirmary of Edinburgh, Edinburgh
Hull York Medical School Centre for Cardiovascular and Metabolic Research, Hull
Glenfield Hospital, Leicester
Kings College Hospital, London
Queen Anne Street Medical Centre, London
Lead Sponsor
Genentech, Inc.
INDUSTRY